Enliven Therapeutics Inc (ELVN)

Currency in USD
41.580
-0.030(-0.07%)
Closed·
41.5800.000(0.00%)
·
Earnings results expected in 15 days
ELVN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
40.71542.991
52 wk Range
14.78548.530
Key Statistics
Prev. Close
41.61
Open
41.79
Day's Range
40.715-42.991
52 wk Range
14.785-48.53
Volume
439.19K
Average Volume (3m)
1.1M
1-Year Change
100.1962%
Book Value / Share
7.74
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ELVN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
51.286
Upside
+23.34%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Enliven Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 51.286
(+23.34% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Clear Street
Buy55.00+32.28%36.00MaintainApr 27, 2026
H.C. Wainwright
Buy56.00+34.68%-MaintainApr 08, 2026
Jones Trading
Buy45.00+8.23%-New CoverageApr 06, 2026
H.C. Wainwright
Buy56.00+34.68%48.00MaintainMar 26, 2026
Clear Street
Buy36.00-13.42%-MaintainMar 25, 2026

Earnings

Latest Release
Mar 03, 2026
EPS / Forecast
-0.48 / -0.46
Revenue / Forecast
-- / 8.33K
EPS Revisions
Last 90 days

ELVN Income Statement

Compare ELVN to Peers and Sector

Metrics to compare
ELVN
Peers
Sector
Relationship
P/E Ratio
−23.8x−2.7x−0.5x
PEG Ratio
−7.410.130.00
Price/Book
5.4x2.7x2.6x
Price / LTM Sales
-275.9x3.3x
Upside (Analyst Target)
25.0%69.1%47.1%
Fair Value Upside
Unlock12.5%6.2%Unlock

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
19.20M32.10%800.47M
Other Institutional Investors
59.48M67.90%2.48B
Public Companies & Retail Investors
0.000.00%0.00
Total
78.68M100.00%3.28B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
OrbiMed Advisors LLC13.31%7,959,538331,196
Orbimed Private Investments VII, LP12.81%7,663,349318,872

People Also Watch

107.580
AXTI
+1.49%
9.990
ERAS
-1.48%
180.750
AAOI
+4.49%
16.7110
LWLG
+5.83%
21.400
AMPX
+5.00%

FAQ

What Is the Enliven Therapeutics (ELVN) Stock Price Today?

The Enliven Therapeutics stock price today is 41.580 USD.

What Stock Exchange Does Enliven Therapeutics Trade On?

Enliven Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Enliven Therapeutics?

The stock symbol for Enliven Therapeutics is "ELVN."

What Is the Enliven Therapeutics Market Cap?

As of today, Enliven Therapeutics market cap is 2.480B USD.

What Is Enliven Therapeutics's Earnings Per Share (TTM)?

The Enliven Therapeutics EPS (TTM) is -1.830.

When Is the Next Enliven Therapeutics Earnings Date?

Enliven Therapeutics will release its next earnings report on May 20, 2026.

From a Technical Analysis Perspective, Is ELVN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has Enliven Therapeutics Stock Split?

Enliven Therapeutics has split 1 times.

How Many Employees Does Enliven Therapeutics Have?

Enliven Therapeutics has 60 employees.

What is the current trading status of Enliven Therapeutics (ELVN)?

As of May 05, 2026, Enliven Therapeutics (ELVN) is trading at a price of 41.580 USD, with a previous close of 41.610 USD. The stock has fluctuated within a day range of 40.715 USD to 42.991 USD, while its 52-week range spans from 14.785 USD to 48.530 USD.

What Is Enliven Therapeutics (ELVN) Price Target According to Analysts?

The average 12-month price target for Enliven Therapeutics is 51.286 USD, with a high estimate of 60 USD and a low estimate of 41 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.34% Upside potential.

What Is the ELVN Premarket Price?

ELVN's last pre-market stock price is 41.200 USD. The pre-market share volume is 5,680.000, and the stock has decreased by -0.410, or -0.990%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.